209 related articles for article (PubMed ID: 21802118)
1. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
[TBL] [Abstract][Full Text] [Related]
2. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
3. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
[TBL] [Abstract][Full Text] [Related]
4. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
5. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
Chauchard M; Benali K; Papo T; Sacre K
Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
[TBL] [Abstract][Full Text] [Related]
7. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
[No Abstract] [Full Text] [Related]
8. Performance of
Robin P; van Es N; Le Roux PY; Rondina M; Lecumberri R; Beckers M; Le Gal G; Salaun PY
Thromb Res; 2020 Oct; 194():153-157. PubMed ID: 32788108
[TBL] [Abstract][Full Text] [Related]
9.
Delluc A; Robin P
Thromb Res; 2022 May; 213 Suppl 1():S42-S45. PubMed ID: 36210560
[No Abstract] [Full Text] [Related]
10. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism.
Coyle K; Carrier M; Lazo-Langner A; Shivakumar S; Zarychanski R; Tagalakis V; Solymoss S; Routhier N; Douketis J; Coyle D
Thromb Res; 2017 Mar; 151():67-71. PubMed ID: 28160670
[TBL] [Abstract][Full Text] [Related]
13. Effect of testing for cancer on cancer- and venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010837. PubMed ID: 28832905
[TBL] [Abstract][Full Text] [Related]
14. Multimodal imaging and detection approach to 18F-FDG-directed surgery for patients with known or suspected malignancies: a comprehensive description of the specific methodology utilized in a single-institution cumulative retrospective experience.
Povoski SP; Hall NC; Murrey DA; Chow AZ; Gaglani JR; Bahnson EE; Mojzisik CM; Kuhrt MP; Hitchcock CL; Knopp MV; Martin EW
World J Surg Oncol; 2011 Nov; 9():152. PubMed ID: 22112047
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of FDG PET/CT imaging for venous thromboembolic disorders: preliminary results from a prospective, observational pilot study.
Hess S; Madsen PH; Iversen ED; Frifelt JJ; Høilund-Carlsen PF; Alavi A
Clin Nucl Med; 2015 Jan; 40(1):e23-6. PubMed ID: 24999680
[TBL] [Abstract][Full Text] [Related]
17. Utility of additional abdominopelvic CT in detecting occult cancer in patients with unprovoked venous thromboembolism.
Vaidyanathan S; Walsh J; Cliffe H; Saleem N; Weston MJ; Lowe AS; Chowdhury FU
Clin Radiol; 2016 Jun; 71(6):501-6. PubMed ID: 27005017
[TBL] [Abstract][Full Text] [Related]
18. Unprovoked venous thromboembolism in women over 40: is screening for occult malignancy with mammography and abdominopelvic CT of benefit?
Healy NA; Daley FC; Sinnatamby R
Clin Radiol; 2020 Oct; 75(10):757-762. PubMed ID: 32646605
[TBL] [Abstract][Full Text] [Related]
19. Whole-Body
Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
